Navigation Links
Alzheimer's disease: The first prevention study of its kind
Date:9/21/2011

This press release is available in French.

Researchers at the Douglas Mental Health University Institute, in Montreal, Quebec, are about to launch the first epidemiological study on the prevention of Alzheimer's disease.

"As far as we know, this is the first study of its kind to be carried out anywhere in the world," states John Breitner, the study's lead investigator and Director of the new Centre for Studies on Prevention of Alzheimer's Disease (StoP-Alzheimer). Dr John Breitner and Dr Judes Poirier, the Centre's Associate Director, will be recruiting 250 healthy adults aged 60 or over, who have (or had) a parent, brother or sister with Alzheimer's disease, in order to learn which methods are most effective at preventing this neurodegenerative condition.

Using a combined diagnostic approach of brain imaging and cerebrospinal fluid analysis, the researchers will observe their subjects' biomarkers for a period of ten years to find out which preventative agents can stop the disease from developing, long before symptoms appear. The preventative agents involvedfive in allhave already shown promising results in previous studies. They are anti-inflammatory medications, insulin, physical activity, the Mediterranean diet, and drugs stimulating the production of a protein connected to the apoE gene.

The future of Alzheimer's research

For more than a decade, research into the treatment of Alzheimer's disease, whether pharmacological or other, has not produced the desired results. To date, only some symptoms relating to cognitive decline or memory loss can be treated. Observations by scientists suggest that the focus should shift to prevention and that money should be invested in major studies into this aspect of the disease. "Alzheimer's is a public health crisis that could take on catastrophic proportions in the coming years. It is imperative that we find the prevention strategies that are most likely to succeed," stresses Dr Poirier.

Centre for Studies on Prevention of Alzheimer's Disease

Supported financially by McGill University and the professorial chair funded by pharmaceutical giant Pfizer, the Centre for Studies on Prevention of Alzheimer's Disease, based at the Douglas Institute, is committed to finding ways to stop the disease's progress long before any symptoms are noticed. The Centre will be able to draw on the findings of more than twenty scientists already studying brain aging. This new study by Dr Breitner and Dr Poirier is the first in a series that will be developed at the Centre.

"What we will be doing is similar to the work done on preventing heart disease, that is, to intervene before the damage is done," explains Dr Poirier.

The impact of disease prevention

Preventing the disease from manifesting itself, even if only for a few years, would have a huge impact on future generations, on families, on society, and on the health care system as a whole.

  • Postponing the disease's symptoms for two years represents 30% fewer cases for the current generation.

  • Push the symptoms back by five years, and the number of cases is cut by half within one generation. It's a crisis situation. Every year, the costs attributable to Alzheimer's disease are estimated to be between $6 billion and $8 billion in Canada alone.

  • Half a million Canadians suffer from Alzheimer's or a related dementia71,000 of those are under 75 years of age (Alzheimer's Society of Montreal).

  • A person who has a parent with Alzheimer's is two to three times more likely to develop the disease.


'/>"/>

Contact: Marie france Coutu
marie-france.coutu@douglas.mcgill.ca
514-835-3236
Douglas Mental Health University Institute
Source:Eurekalert

Related medicine news :

1. Thyroid Disease: The Hidden Epidemic
2. Understanding causes of cancer and chronic disease: The Canadian Partnership for Tomorrow Project
3. Patients at high risk of recurrences of heart disease: Breakthrough in prevention
4. Crohn's & Colitis Foundation National Event Helping Women Manage Inflammatory Bowel Disease: Two Women Physician Experts and Researchers in IBD on Interactive Webcast/Teleconference
5. HIV/AIDS treatment curbs spread of disease: UBC-BC CfE study
6. Chronic Lyme disease: How often is it diagnosed and treated?
7. Parkinsons disease: Excess of special protein identified as key to symptoms and possible new target for treatment with widely used anti-cancer drug imatinib
8. Air Pollution Ups Risk of Chronic Lung Disease: Study
9. Shorter Sleep in Men Ups Risk of Heart Disease: Study
10. Destined for disease: Breast cancer mutation regulates cell fate
11. DMP for coronary heart disease: Current guidelines indicate some need for revision
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... (PRWEB) , ... February 18, 2017 , ... ... today provides the latest information and contact points to easily connect elderly veterans ... care, assisted living, and elder-care funding. It also conveys material on this year's ...
(Date:2/17/2017)... Nashville, TN (PRWEB) , ... February 17, 2017 ... ... Services, Inc. (ISTS) brings its educational assistance management solution to the exhibit floor ... Convention Center in Orlando, Fla. , From Feb. 19–23, 2017, more than ...
(Date:2/17/2017)... ... February 17, 2017 , ... Access today announced that ... Orlando, Fla., February 19-23. Visitors to the company’s booth (#1778) will be the ... patient signatures solution in healthcare . , Since it first introduced Electronic ...
(Date:2/17/2017)... ... February 17, 2017 , ... Cancer diagnostics workflow ... Tri-Conference February 20 – 22 in San Francisco. As part of the Tri-Conference ... molecular pathology workflow solution, as well as its new precision medicine platform, “Crosswalk ...
(Date:2/16/2017)... New York, New York (PRWEB) , ... February ... ... hard work and determination. After what took over 10 years of research, development ... disruptive technology, NTX Technology™. NTX Technology™ is a patented compound of FDA approved ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  AcelRx Pharmaceuticals, ... pharmaceutical company focused on the development and commercialization ... acute pain, announced that Vincent J. Angotti ... a member of the company,s board of directors, ... over two decades of experience leading executive and ...
(Date:2/16/2017)... -- Prescription pain medications provided by "physicians in the months ... opioid use to take hold," according to a new ... The New England Journal of Medicine (NEJM). ... acute pain than in almost any other medical setting," ... the American College of Emergency Physicians. "The challenge is ...
(Date:2/16/2017)... Research and Markets has announced the addition of the "Global ... Cancer Type, Technology - Forecast to 2025" report to their ... The ... a CAGR of around 28.6% over the next decade to reach ... the prominent trends that the market is witnessing include increasing demand ...
Breaking Medicine Technology: